Page 3 - Ramesh Krishnamurthy News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Vivimed Labs jumped 4.77% to Rs 29.65 after the company announced the first export shipment of famotidine tablets to Canada.Vivimed Labs announced the export of first shipment of famotidine tablets (40mg and 20mg) to Canada. The drug is manufactured at the company's Hyderabad facility. Famotidine is an histamine H₂ receptor antagonist medication that decreases stomach acid production. The drug is used for the relief of heartburn, indigestion, upset stomach, sour stomach due to excess stomach acid, hyperacidity and/or acid indigestion. It is also used for the prevention of the symptoms of e...

NEW DELHI: Vivimed Labs, a Hyderabad-based drug maker with a market cap of Rs 260 crore, has had an interesting week. On May 10, it received government approval to manufacture Favipiravir, which lifted its share price up 27 per cent within just 4 sessions. However, it didn’t take much to turn the tides against it. As Covid-19 cases decline gradually, investors are now running away from the counter. On Monday, the scrip hit the 5 per cent lower circuit at Rs 31.20. Investors believe that with the decline in cases, the demand for Favipiravir will also come down. Favipiravir is used for the ...

Vivimed Labs Gains On Receiving Government's Approval To Make Favipiravir Favipiravir is indicated to treat mild to moderate cases of Covid-19 infection and is in short supply owing to rising Covid-19 infections in the country. Updated: May 10, 2021 12:19 pm IST Shares of the Hyderabad-based drug maker - Vivimed Labs - were locked in a five per cent upper circuit at Rs 28.45 after it received government of India's approval to manufacture and market Favipiravir Tablet 200 mg and 400 mg for Indian market. "Vivimed Labs Limited, a niche specialty chemicals and pharmaceuticals company, announ...

Approval for Vivimed to manufacture Favipiravir tablets May 10, 2021 To be used for treatment of mild to moderate cases of Covid-19 Vivimed Labs Limited, a Specialty Chemicals and Pharmaceuticals company, has announced it has received Government of India (Director General of Health Services) approval for manufacture and marketing of Favipiravir tablet of 200 mg & 400 mg under Vivimed’s own brand Favulous across India. These are used for the treatment of mild to moderate cases of Covid-19. Favipiravir is one of the leading oral anti-viral treatment approved in various countries for the pote...

Vivimed Labs hit an upper circuit of 5% at Rs 28.45 after the company announced the receipt of Government of India (Director General of Health Services) approval to manufacture and market Favipiravir tablet 200 mg & 400 mg for Indian market.The company will sell Favipiravir tablets under its own brand name "Favulous" across India. The drug is approved to be used to treat mild-to-moderate Covid-19 in adults under restricted emergency use. Favipiravir registered highest sales in the month of April 2021. Since the launch of the drug last June, Glenmark Pharma has registered a turnover of Rs 762 ...